

Special Issue

Gut Microbiota and Cancers of the GI Tract: Role in Regulation, Prevention and Therapy

Message from the Guest Editors

The prevalence of gastrointestinal (GI) tract malignancies is steadily increasing worldwide. Currently, GI cancers account for approximately 25% of all newly diagnosed cancer cases and are responsible for one-third of global cancer-related mortality. Alterations to the composition of the gastrointestinal microbiota are increasingly being recognised as influential in the pathogenesis of GI malignancies. Despite growing evidence, the molecular and cellular mechanisms driving this association are still not well understood. Certain bacterial taxa have been associated with tumorigenic processes, whereas others exhibit a protective role or potential antineoplastic properties. Importantly, new evidence is emerging that by modulating the tumour microenvironment, the gut microbiota affects the success of various therapeutic approaches.

For this Special Issue, we invite submissions that advance our understanding of the fundamental mechanisms by which the microbiota influences the development of gastrointestinal (GI) cancers, as well as translational and clinical research exploring the impact of the microbiota on the efficacy and outcomes of anti-cancer therapies.

Guest Editors

Dr. Luka Bočkor

Institute for Anthropological Research, Zagreb, Croatia

Dr. Jurica Žučko

Faculty of Food Technology and Biotechnology, University of Zagreb, Zagreb, Croatia

Deadline for manuscript submissions

30 November 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/239313

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).